A phase II trial of topotecan in patients with previously untreated pancreatic cancer

Seamus O'Reilly, Ross C Donehower, Eric K. Rowinsky, Sarah Ord, Louise B. Grochow

Research output: Contribution to journalArticle

Abstract

Because currently available chemotherapeutic agents are largely ineffective in the treatment of pancreatic cancer, novel treatments are urgently needed to improve outcomes in this disease. The purpose of this phase II study was to evaluate the anti-tumor activity of topotecan, a hydrophilic camptothecin analog that has demonstrated a wide range of anti-tumor activity in preclinical and phase I studies. Topotecan was administered as a 30 min infusion at a dose of 1.5 mg/m2/day for five consecutive days every 3 weeks, to chemotherapy-naive patients with advanced pancreatic cancer. Neutropenia was the principal toxicity of topotecan on this dosing schedule. No significant anti-tumor responses were observed in 27 patients with measurable disease. The median time to disease progression was 7 weeks and the median survival duration was 17.5 weeks. Thus, topotecan, administered on this schedule, is ineffective for patients with pancreatic carcinoma.

Original languageEnglish (US)
Pages (from-to)410-414
Number of pages5
JournalAnti-Cancer Drugs
Volume7
Issue number4
DOIs
StatePublished - 1996

Fingerprint

Topotecan
Pancreatic Neoplasms
Appointments and Schedules
Camptothecin
Neoplasms
Neutropenia
Disease Progression
Drug Therapy
Survival
Therapeutics

Keywords

  • Pancreatic cancer
  • Topotecan

ASJC Scopus subject areas

  • Pharmacology
  • Cancer Research
  • Oncology

Cite this

A phase II trial of topotecan in patients with previously untreated pancreatic cancer. / O'Reilly, Seamus; Donehower, Ross C; Rowinsky, Eric K.; Ord, Sarah; Grochow, Louise B.

In: Anti-Cancer Drugs, Vol. 7, No. 4, 1996, p. 410-414.

Research output: Contribution to journalArticle

O'Reilly, Seamus ; Donehower, Ross C ; Rowinsky, Eric K. ; Ord, Sarah ; Grochow, Louise B. / A phase II trial of topotecan in patients with previously untreated pancreatic cancer. In: Anti-Cancer Drugs. 1996 ; Vol. 7, No. 4. pp. 410-414.
@article{c4132149770943c097e6e52c88b62b4a,
title = "A phase II trial of topotecan in patients with previously untreated pancreatic cancer",
abstract = "Because currently available chemotherapeutic agents are largely ineffective in the treatment of pancreatic cancer, novel treatments are urgently needed to improve outcomes in this disease. The purpose of this phase II study was to evaluate the anti-tumor activity of topotecan, a hydrophilic camptothecin analog that has demonstrated a wide range of anti-tumor activity in preclinical and phase I studies. Topotecan was administered as a 30 min infusion at a dose of 1.5 mg/m2/day for five consecutive days every 3 weeks, to chemotherapy-naive patients with advanced pancreatic cancer. Neutropenia was the principal toxicity of topotecan on this dosing schedule. No significant anti-tumor responses were observed in 27 patients with measurable disease. The median time to disease progression was 7 weeks and the median survival duration was 17.5 weeks. Thus, topotecan, administered on this schedule, is ineffective for patients with pancreatic carcinoma.",
keywords = "Pancreatic cancer, Topotecan",
author = "Seamus O'Reilly and Donehower, {Ross C} and Rowinsky, {Eric K.} and Sarah Ord and Grochow, {Louise B.}",
year = "1996",
doi = "10.1097/00001813-199606000-00006",
language = "English (US)",
volume = "7",
pages = "410--414",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - A phase II trial of topotecan in patients with previously untreated pancreatic cancer

AU - O'Reilly, Seamus

AU - Donehower, Ross C

AU - Rowinsky, Eric K.

AU - Ord, Sarah

AU - Grochow, Louise B.

PY - 1996

Y1 - 1996

N2 - Because currently available chemotherapeutic agents are largely ineffective in the treatment of pancreatic cancer, novel treatments are urgently needed to improve outcomes in this disease. The purpose of this phase II study was to evaluate the anti-tumor activity of topotecan, a hydrophilic camptothecin analog that has demonstrated a wide range of anti-tumor activity in preclinical and phase I studies. Topotecan was administered as a 30 min infusion at a dose of 1.5 mg/m2/day for five consecutive days every 3 weeks, to chemotherapy-naive patients with advanced pancreatic cancer. Neutropenia was the principal toxicity of topotecan on this dosing schedule. No significant anti-tumor responses were observed in 27 patients with measurable disease. The median time to disease progression was 7 weeks and the median survival duration was 17.5 weeks. Thus, topotecan, administered on this schedule, is ineffective for patients with pancreatic carcinoma.

AB - Because currently available chemotherapeutic agents are largely ineffective in the treatment of pancreatic cancer, novel treatments are urgently needed to improve outcomes in this disease. The purpose of this phase II study was to evaluate the anti-tumor activity of topotecan, a hydrophilic camptothecin analog that has demonstrated a wide range of anti-tumor activity in preclinical and phase I studies. Topotecan was administered as a 30 min infusion at a dose of 1.5 mg/m2/day for five consecutive days every 3 weeks, to chemotherapy-naive patients with advanced pancreatic cancer. Neutropenia was the principal toxicity of topotecan on this dosing schedule. No significant anti-tumor responses were observed in 27 patients with measurable disease. The median time to disease progression was 7 weeks and the median survival duration was 17.5 weeks. Thus, topotecan, administered on this schedule, is ineffective for patients with pancreatic carcinoma.

KW - Pancreatic cancer

KW - Topotecan

UR - http://www.scopus.com/inward/record.url?scp=0029934111&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029934111&partnerID=8YFLogxK

U2 - 10.1097/00001813-199606000-00006

DO - 10.1097/00001813-199606000-00006

M3 - Article

C2 - 8826609

AN - SCOPUS:0029934111

VL - 7

SP - 410

EP - 414

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 4

ER -